Role of immunotherapy in the treatment of COVID-19 disease

Zahra Javadi, Hossein Javid ©

Role of immunotherapy in the treatment of COVID-19 disease

کد: G-47108

نویسندگان: Zahra Javadi, Hossein Javid ©

زمان بندی: زمان بندی نشده!

برچسب: بیوشیمی

دانلود: دانلود پوستر

خلاصه مقاله:

Background and Aim

Immune-based therapies have found their way in the treatment of a wide range of diseases and recently, they turned into an option for the management of COVID-19 disease. The failure of the anti-viral agents, glucocorticoids, and immunoglobulins in the treatment of the severe cases of COVID-19 disease as well as the partial success of convalescent plasma from patients that have recovered from COVID-19 have suggested that immunotherapies might do well in the treatment of this disease. Recently, the efficacy of natural killer (NK) cells-based therapies, inhibitors of IL-6, JAK inhibitors, mesenchymal stem cell (MSC)-based therapy, and regulatory T (Treg) cell-based therapy against the SARS-CoV-2 virus have been tested in pre-clinical and clinical investigations. MSCs, for example, have shown to not only could control the SARS-CoV-2-mediated cytokine storm but also repair pulmonary tissue damage through secreting several growth factors.




Thus far, several clinical trials are evaluating the effect of MSCs against severe cases of COVID-19. Adoptive therapy with Tregs was also shown to be a valuable approach for restoring the balance of immune responses in COVID-19 patients. By using engineering methods, Tregs could carry markers that facilitate their homing to the lungs, where these cells could shut down the SARS-CoV-2 virus cytokine storm. The early results of the pre-clinical studies suggested that Treg transplantation could prevent lung injury, enhance lung epithelium regeneration, and reduce inflammatory responses.


Taken together, although it is early to suggest whether immunotherapies are beneficial for COVID-19 patients, it seems that manipulating the immune profile of patients could be one of the best approaches to improve SARS-CoV-2 virus-induced lymphopenia and restore inflammatory responses.


COVID-19 disease; Immunotherapies; NK cell-based therapies; MSC-based therapies; regulatory T cells.

دیدگاه ها (0)

تاکنون دیدگاهی منتشر نشده است. شما اولین نفر باشید!

ارسال یک دیدگاه

ارسال دیدگاه توسط مدیریت بسته شده است.